| Drug Name |
Methylnaltrexone bromide |
| Drug ID |
BADD_D01430 |
| Description |
Methylnaltrexone is a pheriphally-acting μ-opioid antagonist that acts on the gastrointestinal tract to decrease opioid-induced constipation without producing analgesic effects or withdrawal symptoms. It is also a weak CYP2D6 inhibitor. FDA approved in 2008. |
| Indications and Usage |
Treatment of opioids induced constipation in palliative patients that are inadequately responding to laxative therapy. |
| Marketing Status |
approved |
| ATC Code |
A06AH01 |
| DrugBank ID |
DB06800
|
| KEGG ID |
D06618
|
| MeSH ID |
C032257
|
| PubChem ID |
5361917
|
| TTD Drug ID |
D03YVO
|
| NDC Product Code |
65649-150; 65649-551; 0406-1251; 65649-552; 66406-0219 |
| UNII |
RFO6IL3D3M
|
| Synonyms |
methylnaltrexone | quaternary ammonium naltrexone | (5alpha)-17-(cyclopropylmethyl)-3,14-dihydroxy-17-methyl-4,5-epoxymorphinan-17-ium-6-one | 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinanium-6-one | morphinanium, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-6-oxo-, (5alpha)- | morphinan-17-ium-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-, (5alpha)- | naltrexone methylbromide | N-methylnaltrexone bromide | morphinan-17-ium-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-, bromide, (5alpha,17R)- | naltrexone MB | naltrexone methobromide | methylnaltrexone bromide | methyl-naltrexone hydrobromide | MRZ 2663BR | Relistor | MRZ-2663 | naltrexonium methiodide |
